Anti-Mouse CD11a Antibody (FD441.8) is an anti-mouse CD11a IgG2b antibody inhibitor derived from the host Rat. Anti-Mouse CD11a Antibody (FD441.8) can neutralize CD11a also known as LFA-1α (lymphocyte function-associated antigen 1 alpha ). Anti-Mouse CD11a Antibody (FD441.8) can be used for the researches of inflammation, immunology and cancer, such as transplant and leukemia [1] [2] [3].
In Vivo, Anti-Mouse CD11a Antibody (FD441.8) (31.25 μg, i.p., every 3 days from one day before transplantation) extends graft survival and increases acceptance rate in rat islet xenotransplant mice[1]. Anti-Mouse CD11a Antibody (FD441.8) (300 μg, i.v., at day of hapten-challenge) inhibits CXCL1 production in dinitrofluorobenzene (DNFB) sensitized wild-type mice[2]. Anti-Mouse CD11a Antibody (FD441.8) (T cells pretreated with 50 μg/mL FD441.8 for 30 mins) enhances lung egress and trafficking to the bone marrow in mice[3].
References:
[1]. Ashkenazi E, et al. Pancreatic islet xenograft survival in mice is extended by a combination of alpha-1-antitrypsin and single-dose anti-CD4/CD8 therapy. PLoS One. 2013 May 22;8(5):e63625.
[2]. Kish DD, et al. Hapten application to the skin induces an inflammatory program directing hapten-primed effector CD8 T cell interaction with hapten-presenting endothelial cells. J Immunol. 2011 Feb 15;186(4):2117-26.
[3]. James SE, et al. Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. Blood. 2009 Dec 24;114(27):5454-63.
In Vivo, Anti-Mouse CD11a Antibody (FD441.8) (31.25 μg, i.p., every 3 days from one day before transplantation) extends graft survival and increases acceptance rate in rat islet xenotransplant mice[1]. Anti-Mouse CD11a Antibody (FD441.8) (300 μg, i.v., at day of hapten-challenge) inhibits CXCL1 production in dinitrofluorobenzene (DNFB) sensitized wild-type mice[2]. Anti-Mouse CD11a Antibody (FD441.8) (T cells pretreated with 50 μg/mL FD441.8 for 30 mins) enhances lung egress and trafficking to the bone marrow in mice[3].
References:
[1]. Ashkenazi E, et al. Pancreatic islet xenograft survival in mice is extended by a combination of alpha-1-antitrypsin and single-dose anti-CD4/CD8 therapy. PLoS One. 2013 May 22;8(5):e63625.
[2]. Kish DD, et al. Hapten application to the skin induces an inflammatory program directing hapten-primed effector CD8 T cell interaction with hapten-presenting endothelial cells. J Immunol. 2011 Feb 15;186(4):2117-26.
[3]. James SE, et al. Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. Blood. 2009 Dec 24;114(27):5454-63.